SEC Form 4 · accession 0001104659-17-028860
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Darlene M Deptula-Hicks
Officer — Chief Financial Officer
Period of report
May 1, 2017
Accepted (ET)
May 2, 2017 · 3:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.74 | May 1, 2016 | A | 175,000 | A | — | May 1, 2027 | Common Stock | 175,000 | 175,000 | D |
Explanation of responses
- F125% of the total shares vest on 05/01/2018, and the remaining shares vest in substantially equal monthly installments over the following 36 months, to be fully vested on 05/01/2021.